Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 93
Filter
1.
Orthopade ; 41(4): 313-24; quiz 325-6, 2012 Apr.
Article in German | MEDLINE | ID: mdl-22476423

ABSTRACT

The clinical finding of flatfoot is characterized by a flattening of the medial longitudinal arch and valgus deformity of the hindfoot. The differential diagnosis of flatfoot is the physiological, flexible, contracted flatfoot, which occurs as a congenital or acquired deformity. Congenital flatfoot deformity requires early intensive therapy, while a flexible flatfoot in children has a good prognosis and conservative treatment usually leads to a stable and sufficient load-bearing foot. Severe flatfoot in children can be corrected successfully by simple, minimally invasive procedures. In adults with symptomatic flatfoot, which usually occurs due to an insufficiency of the tendon of the tibialis posterior, conservative therapy with insoles, shoe modifications and physiotherapeutic measures can lead to significant improvement, otherwise surgical correction is recommended. Early, stage-appropriate therapy helps to prevent an impending decompensation of the hindfoot.


Subject(s)
Exercise Therapy/methods , Flatfoot/diagnosis , Flatfoot/therapy , Minimally Invasive Surgical Procedures/methods , Orthotic Devices , Plastic Surgery Procedures/methods , Shoes , Adult , Child , Humans
2.
J Neural Transm Suppl ; (72): 57-67, 2007.
Article in English | MEDLINE | ID: mdl-17982879

ABSTRACT

Oxidative stress is central to neuronal damage in neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. In consequence, activation of the cerebral oxidative stress defence is considered as a promising strategy of therapeutic intervention. Here we demonstrate that the flavone luteolin confers neuroprotection against oxidative stress via activation of the nuclear factor erythroid-2-related factor 2 (Nrf2), a transcription factor central to the maintenance of the cellular redox homeostasis. Luteolin protects rat neural PC12 and glial C6 cells from N-methyl-4-phenyl-pyridinium (MPP+) induced toxicity in vitro and effectively activates Nrf2 as shown by ARE-reporter gene assays. This protection critically depends on the activation of Nrf2 since downregulation of Nrf2 by shRNA completely abrogates the protection of luteolin in vitro. Furthermore, the neuroprotective effect of luteolin is abolished by the inhibition of the luteolin-induced ERK1/2-activation. Our results highlight the relevance of Nrf2 for neural cell survival conferred by flavones. In particular, we identified luteolin as a promising lead for the search of orally available, blood brain barrier permeable compounds to support the therapy of neurodegenerative disorders.


Subject(s)
1-Methyl-4-phenylpyridinium/toxicity , Cell Survival/drug effects , Flavonoids/pharmacology , Genes, Reporter/genetics , Herbicides/toxicity , Luteolin/pharmacology , NF-E2-Related Factor 2/genetics , Oxidative Stress/physiology , Proteins/genetics , Tumor Cells, Cultured/drug effects , Animals , Antioxidants , Brain/metabolism , Cell Survival/genetics , Gene Expression/drug effects , In Vitro Techniques , Intracellular Signaling Peptides and Proteins , Kelch-Like ECH-Associated Protein 1 , Oxidative Stress/genetics , PC12 Cells , RNA, Small Interfering/genetics , Rats , Up-Regulation/drug effects
3.
Gynecol Obstet Fertil ; 33(10): 813-8, 2005 Oct.
Article in French | MEDLINE | ID: mdl-16154375

ABSTRACT

Mouse embryonic stem cells derive from the inner cell mass of the blastocyst and give rise to the three primitive embryonic layers, which later will form all the different tissue types of an adult. Embryonic stem cells are thus defined as totipotent cells. In vitro, these cells can give rise to all the somatic cells. Different laboratories have now shown that cultured embryonic stem cells can also differentiate into germline cells. By using the transcription factor Oct-4 as a tool for the visualization of germ cells, it has been shown the derivation of oocytes from mouse embryonic stem cells. These works should contribute to various areas, including therapeutic cloning which associates nuclear transfer and selective production of a specific cell type.


Subject(s)
Blastocyst/physiology , Embryo, Mammalian/cytology , Oogenesis , Totipotent Stem Cells/physiology , Transcription Factors , Animals , Blastocyst/cytology , Cell Differentiation , Female , Mice , Totipotent Stem Cells/cytology
4.
Cell Death Differ ; 11(1): 80-9, 2004 Jan.
Article in English | MEDLINE | ID: mdl-12970676

ABSTRACT

Cell division cycle 25A (Cdc25A) was shown to colocalise both with nuclear and cytoplasmic proteins. Recently, we have demonstrated that overexpressed Cdc25A promoted the survival of rat 423 cells through indirect activation of PKB-protein kinase B. Using a Cdc25A:ER fusion protein, which can be shuttled from the cytoplasm into the nucleus, the present investigation evidences that the antiapoptotic effect of Cdc25A was restricted to its cytoplasmic localisation in rat 423 cells. In contrast, nuclear Cdc25A overexpression caused dephosphorylation and nuclear retention of the proapoptotic transcription factor Forkhead in rhabdomyosarcoma-like 1 (FKHRL1) in human N.1 ovarian carcinoma cells. This resulted in the increased constitutive expression of the FKHRL1 targets Fas ligand and Bim, and promoted apoptosis. Thus, the Cdc25A oncogene, which was found to be frequently overexpressed in certain human cancers, can increase or decrease the susceptibility to apoptosis depending on the cell-type-specific subcellular distribution.


Subject(s)
Apoptosis/physiology , Cell Nucleus/metabolism , DNA-Binding Proteins/metabolism , Recombinant Proteins/metabolism , Transcription Factors/metabolism , cdc25 Phosphatases/metabolism , Animals , Apoptosis/drug effects , Artificial Gene Fusion , Cell Compartmentation , Cell Cycle Proteins , Cell Line, Tumor , Forkhead Box Protein O1 , Forkhead Box Protein O3 , Forkhead Transcription Factors , Genetic Vectors , Humans , Nerve Tissue Proteins , Rats , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Recombinant Proteins/genetics , Transformation, Genetic , Tumor Necrosis Factor-alpha/pharmacology , cdc25 Phosphatases/genetics
5.
Cell Death Differ ; 9(2): 169-78, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11840167

ABSTRACT

A new synthetic drug, benzamide riboside (BR) exhibited strong oncolytic activity against leukemic cells in the 5-10 microM range. Higher BR-concentrations (20 microM) predominantly induced necrosis which correlated with DNA strand breaks and subsequent depletion of ATP- and dATP levels. Replenishment of the ATP pool by addition of adenosine prevented necrosis and favoured apoptosis. This effect was not a pecularity of BR-treatment, but was reproduced with high concentrations of all trans-retinoic acid (120 microM) and cyanide (20 mM). Glucose was also capable to suppress necrosis and to favour apoptosis of HL-60 cells, which had been treated with necrotic doses of BR and cyanide. Apoptosis eliminates unwanted cells without affecting the microenvironment, whereas necrosis causes severe inflammation of surrounding tissues due to spillage of cell fluids into the peri-cellular space. Thus, the monitoring and maintenance of cellular energy pools during therapeutic drug treatment may help to minimize nonspecific side effects and to improve attempted drug effects.


Subject(s)
Adenosine Triphosphate/physiology , Antineoplastic Agents/toxicity , Apoptosis , Necrosis , Nucleosides/toxicity , Adenosine/pharmacology , Adenosine Triphosphate/analysis , Benzamides/pharmacology , Comet Assay , DNA Damage , Deoxyadenine Nucleotides/analysis , Deoxycytosine Nucleotides/analysis , Deoxyribonucleotides/analysis , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , HL-60 Cells , Humans , IMP Dehydrogenase/antagonists & inhibitors , Poly(ADP-ribose) Polymerase Inhibitors , Potassium Cyanide/antagonists & inhibitors , Tretinoin/antagonists & inhibitors
6.
Dev Cell ; 1(3): 377-87, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11702949

ABSTRACT

The POU-domain transcription factor Oct4 is essential for the maintenance of the mammalian germline. In this study, we show that the germ cell nuclear factor (GCNF), an orphan nuclear receptor, represses Oct4 gene activity by specifically binding within the proximal promoter. GCNF expression inversely correlates with Oct4 expression in differentiating embryonal cells. GCNF overexpression in embryonal cells represses Oct4 gene and transgene activities, and we establish a link to transcriptional corepressors mediating repression by GCNF. In GCNF-deficient mouse embryos, Oct4 expression is no longer restricted to the germ cell lineage after gastrulation. Our studies suggest that GCNF is critical in repressing Oct4 gene activity as pluripotent stem cells differentiate and in confining Oct4 expression to the germline.


Subject(s)
DNA-Binding Proteins/metabolism , Embryo, Mammalian/physiology , Germ Cells/physiology , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Antineoplastic Agents/pharmacology , Cell Differentiation/physiology , Cell Line , Cell Lineage , DNA-Binding Proteins/genetics , Embryo, Mammalian/cytology , Embryo, Mammalian/drug effects , Fushi Tarazu Transcription Factors , Gene Expression Regulation , Gene Expression Regulation, Developmental/physiology , Genes, Reporter , Homeodomain Proteins , In Situ Hybridization , Macromolecular Substances , Mice , Mice, Knockout , Nuclear Proteins/metabolism , Nuclear Receptor Co-Repressor 1 , Nuclear Receptor Subfamily 6, Group A, Member 1 , Octamer Transcription Factor-3 , Promoter Regions, Genetic/genetics , Receptors, Cytoplasmic and Nuclear/genetics , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Repressor Proteins/metabolism , Steroidogenic Factor 1 , Transcription Factors/genetics , Transcription Factors/metabolism , Transgenes/genetics , Tretinoin/pharmacology , Two-Hybrid System Techniques
7.
Oncogene ; 20(33): 4542-53, 2001 Jul 27.
Article in English | MEDLINE | ID: mdl-11494150

ABSTRACT

The phosphatase Cdc25A was shown to be a target of the transcription factor c-Myc. Myc-induced apoptosis appeared dependent on Cdc25A expression and Cdc25A over-expression could substitute for Myc-triggered apoptosis. These findings suggested that an important downstream component of Myc-mediated apoptosis was identified. However and in contrast, we recently reported that during TNFalpha-induced apoptosis, which required c-Myc function, Cdc25A was down-regulated in a human carcinoma cell line. We now provide evidence that Cdc25A rendered the non-transformed rat embryonic cell line 423 refractory to apoptosis, which was induced by serum deprivation and in absence of detectable c-myc levels. The survival promoting activity of cdc25A was abolished upon infection of cells with a full-length cdc25A antisense construct. To identify the signaling proteins mediating the survival function of the phosphatase, cdc25A- and akt- over-expressing pooled clones were exposed to selected chemicals, which inhibit or activate key proteins in signaling pathways. Inhibition of apoptosis by SU4984, NF023 and Rapamycin placed Cdc25A and Akt function downstream of FGF.R, PDGF.R, and compensated G-protein- and PP2A- activity. Interestingly, upon treatment with LY-294002, cdc25A- and akt- over-expressing clones exhibited similar apoptotic patterns as control cells, which indicates that neither Akt- nor Cdc25A-mediated survival functions are dependent on PI.3 kinase activity in rat 423 cells. In cdc25A-overexpressing cells increased levels of serine 473 phosphorylated Akt were found, which co-precipitated with Cdc25A and Raf1. Since activation of proteins requires dephosphorylation of particular residues in addition to site-specific phosphorylation, the anti-apoptotic effect of Cdc25A might derive from its participation in a multimeric protein complex with phosphoAkt and Raf1, two prominent components of survival pathways.


Subject(s)
Apoptosis/drug effects , Arabidopsis Proteins , Culture Media, Serum-Free/pharmacology , cdc25 Phosphatases/physiology , Animals , Cell Line/drug effects , Chromones/pharmacology , Cytokines/pharmacology , Depression, Chemical , Doxycycline/pharmacology , Embryo, Mammalian/cytology , Fibroblast Growth Factor 2/pharmacology , Gene Expression Regulation , Genes, myc , Growth Substances/pharmacology , Intercellular Signaling Peptides and Proteins , Macromolecular Substances , Morpholines/pharmacology , Peptides/pharmacology , Phosphorylation , Piperazines/pharmacology , Plant Proteins/physiology , Platelet-Derived Growth Factor/pharmacology , Potassium Channels/physiology , Protein Processing, Post-Translational , Proto-Oncogene Proteins c-myc/physiology , Proto-Oncogene Proteins c-raf/physiology , Rats , Recombinant Fusion Proteins/physiology , Sirolimus/pharmacology , Suramin/analogs & derivatives , Suramin/pharmacology , Transfection
8.
Exp Hematol ; 29(5): 623-32, 2001 May.
Article in English | MEDLINE | ID: mdl-11376876

ABSTRACT

OBJECTIVE: Amidox and didox are two polyhydroxy-substituted benzohydroxamic acid derivatives that belong to a new class of ribonucleotide reductase (RR) inhibitors. RR is the rate-limiting enzyme for de novo deoxyribonucleotide synthesis, and its activity is significantly increased in tumor cells in proportion to the proliferation rate. Therefore, RR is a target for antitumor therapy. MATERIALS AND METHODS: HL-60 and K562 leukemia cells were treated with increasing doses of amidox and didox. Thereafter, the mode of cytotoxic drug action was determined by Hoechst 33258/propidium iodide (HO/PI) double staining, annexin binding, DNA fragmentation, and caspase activation. This was correlated to the decrease in dNTP levels. Staining with HO/PI and binding of fluorescein isothiocyanate-conjugated annexin V to externalized phosphatidylserine were used to quantify apoptosis. RESULTS: Low doses of amidox or didox resulted in an increase of apoptotic HL-60 cells within 48 hours. Higher doses (50 microM amidox or 250 microM didox) led to rapid induction of apoptosis, which could be detected as early as 4 hours after treatment. After 48 hours with these concentrations, almost 100% of the HL-60 cells died by apoptosis without an increase in necrosis. K562 cells were found to be resistant to amidox but not to didox. In HL-60 cells, upstream caspase 8 is processed in response to didox, whereas caspases 8 and 9 are processed upon amidox treatment. Didox-induced apoptosis, but not amidox-induced apoptosis, can be correlated with the decrease in dNTP levels. The results suggests that amidox induces several apoptosis mechanisms in HL-60 cells. In contrast, only caspase 9 is activated by didox in K562 cells, and because amidox hardly induces apoptosis in this cell line, no caspase cleavage is observed. CONCLUSIONS: Didox triggers distinct apoptosis pathways in HL-60 and K562 cells.


Subject(s)
Apoptosis/drug effects , Caspase Inhibitors , Caspases/drug effects , Enzyme Inhibitors/pharmacology , Hydroxamic Acids/pharmacology , Neoplasm Proteins/antagonists & inhibitors , Oximes/pharmacology , Ribonucleotide Reductases/antagonists & inhibitors , Annexin A5/metabolism , Caspase 8 , Caspase 9 , DNA Fragmentation , Dose-Response Relationship, Drug , Enzyme Activation/drug effects , Gelsolin/metabolism , HL-60 Cells/drug effects , HL-60 Cells/enzymology , Humans , K562 Cells/drug effects , K562 Cells/enzymology , Phosphatidylserines/metabolism , Pilot Projects , Poly(ADP-ribose) Polymerases/metabolism
10.
Ophthalmologe ; 97(11): 742-7, 2000 Nov.
Article in German | MEDLINE | ID: mdl-11130161

ABSTRACT

PURPOSE: To measure dilation of large retinal branch vessels. METHODS: Diameters of a vessel section of a branch artery and vein were examined by the retinal vessel analyzer. Intraocular pressure (IOP) was increased briefly by an oculo-oscillo-dynamograph. The examination was repeated after 2 weeks. RESULTS: A vessel reaction was found in all volunteers. The mean venous diameter decreased 9.9 +/- 9.4% during the suprasystolic phase of intraocular pressure. A maximal dilation was found in arteries (7.0 +/- 6.2%) and veins (9.3 +/- 5.2%) 1 min after lowering of IOP. The results were reproduced in the second examination for veins in all phases of the examination and for arteries in the middle phase after lowering IOP (4 min). Various changes in mean systolic blood pressure did not significantly affect reproducibility of the vessel reaction. CONCLUSION: The vessel reaction caused by rise in IOP can be measured for single vessel sections. The venous reaction is well reproducible in healthy volunteers. Further research should examine the benefit of this method in the diagnosis and follow-up of glaucoma.


Subject(s)
Intraocular Pressure/physiology , Retinal Vessels/physiology , Vasodilation/physiology , Adult , Blood Pressure/physiology , Female , Humans , Male , Middle Aged , Retinal Vessels/anatomy & histology
11.
J Neurosci ; 20(22): 8485-92, 2000 Nov 15.
Article in English | MEDLINE | ID: mdl-11069956

ABSTRACT

We compared the spike activity of individual neurons in the Aplysia abdominal ganglion with the movement of the gill during the gill-withdrawal reflex. We discriminated four populations that collectively encompass approximately half of the active neurons in the ganglion: (1) second-order sensory neurons that respond to the onset and offset of stimulation of the gill and are active before the movement starts; (2) neurons whose activity is correlated with the position of the gill and typically have a tonic output during gill withdrawal; (3) neurons whose activity is correlated with the velocity of the movement and typically fire in a phasic manner; and (4) neurons whose activity is correlated with both position and velocity. A reliable prediction of the position of the gill is achieved only with the combined output of 15-20 neurons, whereas a reliable prediction of the velocity depends on the combined output of 40 or more cells.


Subject(s)
Aplysia/physiology , Gills/innervation , Models, Neurological , Neurons, Afferent/physiology , Reflex/physiology , Action Potentials/physiology , Algorithms , Animals , Behavior, Animal/physiology , Cell Count , Electric Stimulation , Ganglia, Invertebrate/cytology , Ganglia, Invertebrate/physiology , Gills/physiology , In Vitro Techniques , Neurons, Afferent/classification , Neurons, Afferent/cytology , Predictive Value of Tests , Reaction Time/physiology
13.
Pediatr Res ; 48(5): 679-84, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11044491

ABSTRACT

An inflammatory response and a capillary leak syndrome frequently develop during the treatment of neonatal respiratory failure by extracorporeal membrane oxygenation (ECMO). The present study was performed to investigate leukocyte activation and endothelial cell dysfunction that are associated with prolonged contact of blood components with synthetic surfaces. Laboratory ECMO was performed with fresh human blood at 37 degrees C for 8 h (n = 6). Leukocyte activation was measured by L-selectin (CD62L) and CD18 integrin surface expression and by neutrophil-derived elastase release. To monitor endothelial activation, endothelial cell ICAM-1 (CD54) expression was measured in cultured endothelial cells from human umbilical veins (HUVEC) after incubation with plasma from the ECMO experiments. CD18 integrin expression was found significantly up-regulated on polymorphonuclear neutrophils and monocytes after 2-4 h of laboratory ECMO. L-selectin was reduced on both cell types during the total duration of the experiments. Soluble L-selectin (sCD62L) and total and differential leukocyte counts remained unchanged during the experiment. Neutrophil-derived elastase content was maximal after 8 h of ECMO. Plasma from the ECMO experiments did not induce ICAM-1 expression of cultured HUVEC. We conclude that prolonged contact with synthetic surfaces during ECMO activates phagocytes, which may contribute to the inflammatory response seen in ECMO-treated patients. Activated phagocytes do not accumulate in the extracorporeal system nor release humoral factors inducing ICAM-1 expression on endothelial cells.


Subject(s)
Endothelium, Vascular/physiopathology , Extracorporeal Membrane Oxygenation/adverse effects , Leukocytes/physiology , Models, Biological , CD18 Antigens/metabolism , Cells, Cultured , Endothelium, Vascular/immunology , Humans , In Vitro Techniques , Infant, Newborn , Inflammation/etiology , Intercellular Adhesion Molecule-1/metabolism , L-Selectin/blood , L-Selectin/metabolism , Leukocyte Count , Leukocyte Elastase/blood , Leukocyte Elastase/metabolism , Leukocytes/immunology
14.
Life Sci ; 67(26): 3131-42, 2000 Nov 17.
Article in English | MEDLINE | ID: mdl-11191620

ABSTRACT

Trimidox (3,4,5-trihydroxybenzohydroxamidoxime), a recently synthesized inhibitor of ribonucleotide reductase (RR), was shown to exert anti-proliferative activities in HL-60 and K562 human leukemia cell lines and to prolong the life span of mice inoculated with L1210 mouse leukemia cells. Here we test whether trimidox also exhibits anti-neoplastic properties in ovarian carcinoma cells. Since the mode of action of trimidox on cell fate has not been investigated so far, we addressed this unresolved item and find that this polyhydroxybenzoic acid derivative induces apoptosis of N.1 human ovarian carcinoma cells when tested in growth factor deprived medium. Utilizing an improved analysis, based on Hoechst 33258/propidium iodide double staining, apoptosis is quantified and discriminated from necrosis. Trimidox induces c-myc expression, which is indispensible for apoptosis of N.1 cells, and expression of plasminogen activator/urokinase type (upa), which supports the apoptotic process under more physiological conditions. Surprisingly, trimidox does not block dNTP synthesis in N.1 cells at the concentrations tested and, therefore, trimidox induces apoptosis independent of RR-inhibition. Like TNFalpha or benzamide riboside, which are also inducers of apoptosis of N.1 cells, trimidox also down-regulates the G1 cell cycle phosphatase cdc25A, whereas cyclin D1 becomes up-regulated. This report shows that trimidox destroys human ovarian carcinoma cells by inducing them to undergo apoptosis as well as corroborating previous investigations which demonstrated that apoptosis of these cells depends on c-myc over-expression when survival factors are withdrawn.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis , Benzamidines/pharmacology , Enzyme Inhibitors/pharmacology , Genes, myc , Ovarian Neoplasms/drug therapy , Apoptosis/genetics , Cyclin D1/biosynthesis , Deoxyribonucleotides/metabolism , Drug Screening Assays, Antitumor , Female , Gene Expression/drug effects , Genes, cdc/drug effects , HL-60 Cells , Humans , Ribonucleotide Reductases/antagonists & inhibitors , Tumor Cells, Cultured , Urokinase-Type Plasminogen Activator/biosynthesis , cdc25 Phosphatases/biosynthesis
15.
Mutat Res ; 437(3): 205-17, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10592328

ABSTRACT

Over-expression of the transcription factor c-Myc immortalizes primary cells and transforms in co-operation with activated ras. Therefore, c-myc is considered a proto-oncogene. Since its discovery c-Myc has been shown to render cells growth factor independent, accelerates passage through G1 of the cell cycle, inhibits differentiation and elicits apoptosis. Whereas the effects on immortalization, proliferation and inhibition of differentiation are in conceivable accordance with gain of function, as it is defined for a proto-oncogene, its pro-apoptotic activity disables a straight forward explanation of the physiological role of c-Myc and suggests a highly complex contribution during development. The recent accomplishments in c-Myc research shed some light on the difficile regulatory network which keeps check on c-Myc activity such as by binding to proteins some of which are transcription factors for non-c-Myc targets. Moreover, it was shown that genes are targeted by c-Myc depending on the sequence of flanking regions adjacent to the E-box or in dependence on the availability of binding partners which is most probably specific to the cellular context. Cdc25A and ornithine decarboxylase, both described to be c-Myc targets, have been brought forward as downstream effectors in the induction of proliferation under serum rich conditions, or in the induction of apoptosis when serum factors are limited. These genes seem to be regulated by c-Myc in a cell type-specific manner. H-ferritin, IRP2 and telomerase are the most recently discovered direct targets of c-Myc. The regulation of H-ferritin and IRP2 might explain the potential of c-Myc to promote proliferation and the regulation of telomerase could be responsible for the immortalizing properties of c-Myc. In the future, H-ferritin and telomerase have to be analyzed whether or not these genes are also Myc targets in other cell systems. Although the intense research efforts regarding the function of c-Myc last already two decades the role of this gene is still enigmatic.


Subject(s)
Apoptosis/genetics , Proto-Oncogene Proteins c-myc/genetics , Animals , Cell Division/genetics , Gene Expression Regulation , Humans , Proto-Oncogene Mas , RNA, Messenger/metabolism , Transcription Factors/genetics , Tumor Cells, Cultured
16.
Cell Mol Biol (Noisy-le-grand) ; 45(5): 717-24, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10512201

ABSTRACT

The Oct-4 gene encodes a transcription factor that is essential for maintaining the mouse germline. It is expressed during the earliest stages of embryogenesis, is downregulated during gastrulation, and is thereafter constrained to the germ cell lineage. Retinoic acid induced differentiation of embryonal carcinoma cells is also accompanied by a decrease in Oct-4 expression. We have previously shown that downregulation of Oct-4 expression is mediated by a hormone regulatory element (HRE). This element is located within the basal promoter and overlaps with a GC box that is crucial for Oct-4 promoter activity. The HRE is composed of three direct repeats with 1 and 0 spacing. In this study, we demonstrate that the doublet of direct repeats with 0 spacing (DR0) is bound by two novel factors. The initial repression of Oct-4 by retinoic acid coincides with the disappearance of the first factor (named UCF for undifferentiated cellular factor) and the appearance of a transiently induced factor (TRIF) which forms a larger complex with DR0 in electrophoretic mobility shift assays. These observations support the hypothesis that downregulation of the Oct-4 gene during early mouse embryogenesis involves the repression of its promoter by TRIF.


Subject(s)
Cell Differentiation/genetics , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Animals , Base Sequence , COUP Transcription Factor I , COUP Transcription Factors , Cell Differentiation/drug effects , Gene Expression Regulation , Mice , Molecular Sequence Data , Neoplasms, Experimental/embryology , Octamer Transcription Factor-3 , Receptors, Steroid/genetics , Receptors, Steroid/metabolism , Regulatory Sequences, Nucleic Acid , Repressor Proteins/genetics , Repressor Proteins/metabolism , Stem Cells/drug effects , Transcription Factors/genetics , Transcription Factors/metabolism , Tretinoin/pharmacology
17.
Cell Death Differ ; 6(8): 736-44, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10467347

ABSTRACT

One of the mechanisms of action of a new oncolytic agent, benzamide riboside (BR) is by inhibiting inosine 5'-monophosphate dehydrogenase (IMPDH) which catalyzes the formation of xanthine 5'-monophosphate from inosine 5'-monophosphate and nicotinamide adenine dinucleotide, thereby restricting the biosynthesis of guanylates. In the present study BR (10 - 20 microM) induced apoptosis in a human ovarian carcinoma N.1 cell line (a monoclonal derivative of its heterogenous parent line HOC-7). This was ascertained by DNA fragmentation, TUNEL assay, [poly(ADP)ribose polymerase]-cleavage and alteration in cell morphology. Apoptosis was accompanied by sustained c-Myc expression, concurrent down-regulation of cdc25A mRNA and protein, and by inhibition of Cdk2 activity. Both Cdk2 and cdc25A are G1 phase specific genes and Cdk2 is the target of Cdc25A. These studies demonstrate that BR exhibits dual mechanisms of action, first by inhibiting IMPDH, and second by inducing apoptosis, which is associated with repression of components of the cell cycle that are downstream of constitutive c-Myc expression.


Subject(s)
Apoptosis , Enzyme Inhibitors/metabolism , IMP Dehydrogenase/antagonists & inhibitors , Nucleosides/metabolism , cdc25 Phosphatases/biosynthesis , Adenocarcinoma , Apoptosis/drug effects , Cell Division/drug effects , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Female , Humans , Nucleosides/pharmacology , Ovarian Neoplasms , Tumor Cells, Cultured , cdc25 Phosphatases/genetics
19.
Genes Dev ; 12(13): 2073-90, 1998 Jul 01.
Article in English | MEDLINE | ID: mdl-9649510

ABSTRACT

The POU transcription factor Oct-4 is expressed specifically in the germ line, pluripotent cells of the pregastrulation embryo and stem cell lines derived from the early embryo. Osteopontin (OPN) is a protein secreted by cells of the preimplantation embryo and contains a GRGDS motif that can bind to specific integrin subtypes and modulate cell adhesion/migration. We show that Oct-4 and OPN are coexpressed in the preimplantation mouse embryo and during differentiation of embryonal cell lines. Immunoprecipitation of the first intron of OPN (i-opn) from covalently fixed chromatin of embryonal stem cells by Oct-4-specific antibodies indicates that Oct-4 binds to this fragment in vivo. The i-opn fragment functions as an enhancer in cell lines that resemble cells of the preimplantation embryo. Furthermore, it contains a novel palindromic Oct factor recognition element (PORE) that is composed of an inverted pair of homeodomain-binding sites separated by exactly 5 bp (ATTTG +5 CAAAT). POU proteins can homo- and heterodimerize on the PORE in a configuration that has not been described previously. Strong transcriptional activation of the OPN element requires an intact PORE. In contrast, the canonical octamer overlapping with the downstream half of the PORE is not essential. Sox-2 is a transcription factor that contains an HMG box and is coexpressed with Oct-4 in the early mouse embryo. Sox-2 represses Oct-4 mediated activation of i-opn by way of a canonical Sox element that is located close to the PORE. Repression depends on a carboxy-terminal region of Sox-2 that is outside of the HMG box. Expression, DNA binding, and transactivation data are consistent with the hypothesis that OPN expression is regulated by Oct-4 and Sox-2 in preimplantation development.


Subject(s)
DNA-Binding Proteins/chemistry , DNA-Binding Proteins/physiology , Embryonic Development/genetics , Enhancer Elements, Genetic , Nuclear Proteins/physiology , Sialoglycoproteins/antagonists & inhibitors , Sialoglycoproteins/chemistry , Transcription Factors/chemistry , Amino Acid Sequence , Animals , Base Composition , Base Sequence , Binding Sites/genetics , Blastocyst/metabolism , Blastocyst/physiology , Carcinoma, Embryonal , Cell Differentiation/genetics , Chromatin/isolation & purification , Chromatin/metabolism , DNA-Binding Proteins/isolation & purification , DNA-Binding Proteins/metabolism , Dimerization , Embryo, Mammalian , Female , HMGB Proteins , Introns , Mice , Mice, Inbred Strains , Molecular Sequence Data , Mutagenesis, Site-Directed , Octamer Transcription Factor-3 , Osteopontin , POU Domain Factors , Pregnancy , Protein Conformation , SOXB1 Transcription Factors , Sialoglycoproteins/biosynthesis , Transcription Factors/physiology , Tumor Cells, Cultured
20.
Cell Death Differ ; 5(9): 758-64, 1998 Sep.
Article in English | MEDLINE | ID: mdl-10200535

ABSTRACT

Tumor necrosis factor (TNFs) have been shown to be synthesized by ovarian carcinomas, and may therefore affect tumor cells in an autocrine manner. Therefore, we investigated the effects of recombinant TNFs on ovarian carcinoma cells N.1 and examined expression of the proto-oncogenes c-myc and cdc25A which are known to play a prominent role in apoptosis. TNFalpha elicited apoptosis in N.1 cells within 72 h which was shown by typical morphological changes, DNA fragmentation and signature type cleavage of poly(ADP-ribose) polymerase into a 89 kDa proteolytic peptide. TNFalpha-induced apoptosis was accompanied by constitutive c-Myc expression, although the mRNA level of phosphatase cdc25A was suppressed within 24 h of TNFalpha treatment and the protein level decreased after 48 h. Cdc25A tyrosine phosphatase is an activator of the cdk2-cyclin E complex which allows for cell cycle progression. As expected, we found TNFalpha-mediated Cdc25A down-regulation to inhibit Cdk2 activity. Cdc25A suppression was related to TNFalpha-induced apoptosis but not to a TNFalpha-induced G0 arrest because cyclin D1 expression was unaffected and the gene gas6 (growth arrest specific 6) was not induced. Arresting cells by treatment with genistein prevented TNFalpha-triggered apoptosis and inhibited c-myc expression. TNFalpha-induced apoptosis is not accompanied by cell cycle arrest which may be due to constitutive c-Myc expression, although Cdc25A and Cdk2 activity is also down-regulated. High c-Myc and low Cdc25A activity might present conflicting signals to the cell cycle machinery which are incompatible with cell survival.


Subject(s)
Apoptosis , CDC2-CDC28 Kinases , Intercellular Signaling Peptides and Proteins , Protein Tyrosine Phosphatases/biosynthesis , Tumor Necrosis Factor-alpha/metabolism , cdc25 Phosphatases , Cell Death , Cyclin D1/biosynthesis , Cyclin-Dependent Kinase 2 , Cyclin-Dependent Kinases/metabolism , Humans , Protein Biosynthesis , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...